Sermorelin side effects: the approved-drug safety record vs. the compounded reality

Sermorelin is unusually well-documented for something now sold as a “peptide.” It is a 29-amino-acid analog of human growth-hormone-releasing hormone (GHRH 1–29) — the shortest fragment that retains full GHRH activity — and for years it was a genuine FDA-approved drug, marketed as Geref, used to diagnose and treat growth hormone deficiency in children.^[1]That history matters, because it means the adverse-effect profile of pharmaceutical-grade sermorelin was actually characterized in real patients, rather than being inferred. The catch is that the product most people can buy today is not that drug. This article separates the two.

It was discontinued — for commercial reasons, not safety

A point that gets distorted online: sermorelin (Geref) was taken off the market as a commercial and manufacturing discontinuation, not a safety withdrawal. It was not pulled because patients were harmed. Demand was modest, recombinant growth hormone (somatropin) was the dominant therapy, and the product was retired for business reasons. So “it was discontinued” is true but should not be read as “it was found dangerous.” If anything, the approved-drug-era data describe a tolerable agent — the real modern concern is supply quality, which we get to below.

The adverse effects seen in the approved-drug era

In its clinical use, intravenous single doses and repeated once-daily subcutaneous doses of sermorelin were described as well tolerated.^[1] The most consistently reported reactions were injection-site reactions — pain, redness, or swelling where the shot was given — which is typical for a subcutaneous peptide. Beyond the injection site, the reported adverse events were generally mild and transient: facial flushing, headache, nausea, dizziness, and less commonly difficulty swallowing (dysphagia), vomiting, hyperactivity, pallor, and a tight feeling in the chest. The pivotal once-daily subcutaneous therapy program in growth-hormone-deficient children, run by the Geref International Study Group, accelerated growth while remaining clinically manageable in tolerability, consistent with the broader review record.^[2] In short: real, but unremarkable for an injectable hormone secretagogue.

The mechanism-based concerns worth taking seriously

Sermorelin works by stimulating the pituitary to release the body’s own growth hormone, which in turn raises insulin-like growth factor 1 (IGF-1).^[3] That is a more “physiologic” route than injecting growth hormone directly, and it preserves the pituitary’s own feedback — but it is still deliberately pushing the GH/IGF-1 axis. Stimulating that axis carries the same family of theoretical concerns that apply to growth-hormone therapy generally: effects on glucose handling and insulin sensitivity, fluid retention, joint or muscle aches, and the long-standing biological questions tied to IGF-1 and tissue growth. Studies that gave GHRH (1–29) analogs to older adults showed the axis can be stimulated in that population, which is exactly why caution about chronic, unmonitored use is reasonable.^[4] None of this makes a single diagnostic dose alarming; it is an argument against casual, long-term self-administration without oversight. For the efficacy side of that question, see our main sermorelin evidence review.

The part that has changed: who makes it now

Here is the crucial modern caveat. The sermorelin sold today does not come from the original approved manufacturing line. It is supplied almost entirely through compounding pharmacies and through “research-use-only” channels. Compounded products are prepared under far less stringent oversight than an FDA-approved drug, and outright “research” vials are not held to pharmaceutical manufacturing standards at all — meaning the actual dose, purity, and even the identity of the peptide in the vial are not independently guaranteed. The reassuring tolerability record summarized above belongs to characterized, approved-grade sermorelin. It does not automatically transfer to an uncharacterized compounded or gray-market vial, where the most realistic added risks are off-target contaminants, wrong concentration, and degradation — problems that have nothing to do with sermorelin’s intrinsic pharmacology and everything to do with the supply chain. This is the same supply problem that shadows the wider peptide market, including the GH-secretagogue stacks.^[5]

The honest bottom line

As an approved drug, sermorelin had a benign-looking side-effect profile: mostly injection-site reactions, with occasional flushing, headache, nausea, dizziness, and rare dysphagia, and it was discontinued for commercial — not safety — reasons. The mechanism-based concerns are the ones inherent to nudging the GH/IGF-1 axis, and they argue for medical supervision rather than panic. The genuinely new variable in 2026 is not the molecule; it is the bottle. What was once a quality-controlled pharmaceutical is now mostly a compounded or research-channel product whose contents are far less certain — and that uncertainty, not sermorelin itself, is the most important safety consideration for anyone weighing it today.